Henderson, Nevada – February 17, 2021 – United Health Products, Inc. (OTC: UEEC), (“UHP” or the “Company”), developer of HemoStyp, a patented Neutralized Oxidized Regenerated Cellulose (NORC) hemostatic agent, today announced the publication under the Patent Cooperation Treaty of its international patent application relating to any hydrocolloid format of HemoStyp. The Patent Cooperation Treaty (“PCT”) […]
News
United Health Products Bolsters Management Team and Issues Chairman’s Letter to Shareholders
Henderson, Nevada – December 15, 2020 – United Health Products, Inc. (OTC: UEEC), (“UHP” or the “Company”), developer, manufacturer and marketer of HemoStyp®, a patented Neutralized Oxidized Regenerated Cellulose (NORC) hemostatic agent, today announced the appointment of John Phillips to the newly created position of Vice President, Marketing & Commercial Strategy, effective December 15, 2020. John […]
United Health Products Announces Leadership Changes
Henderson, Nevada – November 24, 2020 – United Health Products, Inc. (OTC: UEEC), (“UHP” or the company”), developer, manufacturer and marketer of HemoStyp®, a patented Neutralized Oxidized Regenerated Cellulose (NORC) hemostatic agent, today announced changes to its senior management team and its Board of Directors. Douglas Beplate, co-founder of the company and currently Chief Executive […]
Journal of Wound Care to Publish Peer Reviewed Article on HemoStyp® Human Trial
Henderson, Nevada – October 26, 2020 – United Health Products, Inc. (OTC: UEEC), (“UHP” or the “Company”), developer, manufacturer and marketer of HemoStyp, a patented Neutralized Oxidized Regenerated Cellulose (NORC) hemostatic agent, today announced that the London based Journal of Wound Care has informed the Company that UHP’s submitted article, Efficacy and Safety of HemoStyp as an Adjunct for […]
United Health Products Submits HemoStyp® Completed PMA Response to FDA
HENDERSON, Nev.–(BUSINESS WIRE)–United Health Products, Inc. (OTCPK: UEEC, “UHP”) today announced that it has submitted documents requested by the FDA in conjunction with its PMA (Class III) application to use HemoStyp in internal surgeries. The company expects the FDA to grant approval to its PMA (Class III) application or request additional information within 30 days. […]
United Health Products Announces HemoStyp® Human Trial Results to be Available on ClinicalTrials.gov
HENDERSON, Nev.–(BUSINESS WIRE)–United Health Products, Inc. (OTCPK: UEEC, “UHP”) today announced that it has uploaded the full results of its Human Trial study, Efficacy and Safety of HemoStyp as an Adjunct for Management of Secondary Hemostasis in the Operative Setting, to the ClinicalTrials.gov website; these results are expected to be made available to the public within 7-14 days. […]